Alendronic acid - Merrion Pharmaceuticals
Alternative Names: Almerol; MER-103Latest Information Update: 31 Jul 2015
At a glance
- Originator Merrion Pharmaceuticals
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoporosis
Most Recent Events
- 31 Jul 2015 Phase-II development was completed for Osteoporosis
- 11 Aug 2008 Development of MER 103 is ongoing
- 18 Jan 2007 Phase-II clinical trials in Osteoporosis in Ireland (PO)